NVAX Novavax Inc

Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August 8, 2018.

Conference call details are as follows:

Date:	August 8, 2018
Time:	4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:	(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode:	5886748
Webcast:	www.novavax.com, “Investors”/ “Events”
Conference call and webcast replay:
Dates:	Starting at 7:30 p.m. ET, August 8, 2018 until 7:30 p.m. ET August 15, 2018
Dial-in number:	(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:	5886748
Webcast:	www.novavax.com, “Investors”/ “Events”, until November 8, 2018

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. It’s RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.

Contact:        

InvestorsErika TrahanSenior Manager, Investor & Public Relationsir@novavax.com240-268-2000

Westwicke PartnersJohn Woolfordjohn.woolford@westwicke.com 443-213-0506

MediaSam BrownMike Beyer mikebeyer@sambrown.com 312-961-2502